

**Amendments to the Claims:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:****In the claims:**

Please amend the claims as follows:

1-45. (canceled)

46. (currently amended) A method for inducing analgesia in a subject, ~~wherein the subject is in need of analgesia mediated in the central nervous system~~, the method comprising delivering across the blood brain barrier of the subject, into the subject's central nervous system, a therapeutically effective amount of an amphiphilic drug-oligomer conjugate comprising an opioid conjugated to an oligomer, wherein the oligomer comprises one or more lipophilic moieties coupled to one or more hydrophilic moieties having a formula:



47-72. (cancelled)

73. (previously presented) The method of claim 46 wherein the subject is a human.

74. (previously presented) The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered to the subject orally.

75. (previously presented) The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered to the subject intravenously.

76. (previously presented) The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered to the subject by a route selected from the group consisting of pulmonary, intradermal, intramuscular, subcutaneous, and intranasal.
77. (cancelled)
78. (previously presented) The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered to the subject as a component of a pharmaceutical composition.
79. (previously presented) The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered to the subject as a component of a pharmaceutical composition formulated for oral administration.
80. (previously presented) The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered to the subject as a component of a pharmaceutical composition formulated for intravenous administration.
81. (currently amended) The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered to the subject as a component of a pharmaceutical composition formulated for administration by a route selected from the group consisting of pulmonary, intradermal, intramuscular, subcutaneous, and intranasal.

82-100. (cancelled)